[go: up one dir, main page]

CL2017003151A1 - Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas - Google Patents

Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas

Info

Publication number
CL2017003151A1
CL2017003151A1 CL2017003151A CL2017003151A CL2017003151A1 CL 2017003151 A1 CL2017003151 A1 CL 2017003151A1 CL 2017003151 A CL2017003151 A CL 2017003151A CL 2017003151 A CL2017003151 A CL 2017003151A CL 2017003151 A1 CL2017003151 A1 CL 2017003151A1
Authority
CL
Chile
Prior art keywords
prepare
methods
formulations
vaccines against
neoplasia
Prior art date
Application number
CL2017003151A
Other languages
English (en)
Inventor
Edward F Fritsch
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of CL2017003151A1 publication Critical patent/CL2017003151A1/es
Priority to CL2019003264A priority Critical patent/CL2019003264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN PARA COMPOSICIÓN DE VACUNA O COMPOSICIÓN INMUNÓGENA CONTRA LA NEOPLASIA PARA EL TRATAMIENTO O PREVENCIÓN DE LA NEOPLASIA EN UN SUJETO Y A MÉTODOS PARA PREPARAR LA MISMA.</p>
CL2017003151A 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas CL2017003151A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172890P 2015-06-09 2015-06-09

Publications (1)

Publication Number Publication Date
CL2017003151A1 true CL2017003151A1 (es) 2018-04-06

Family

ID=56236097

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003151A CL2017003151A1 (es) 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Country Status (19)

Country Link
US (1) US20190060428A1 (es)
EP (1) EP3307303A2 (es)
JP (2) JP2018521028A (es)
KR (1) KR20180016531A (es)
CN (1) CN107921107A (es)
AU (1) AU2016276704A1 (es)
CA (1) CA2988135A1 (es)
CL (2) CL2017003151A1 (es)
CO (1) CO2017012893A2 (es)
CR (1) CR20180015A (es)
EC (1) ECSP18001613A (es)
HK (2) HK1253271A1 (es)
IL (1) IL256173A (es)
MX (1) MX2017015881A (es)
PE (1) PE20180601A1 (es)
PH (1) PH12017502233A1 (es)
RU (2) RU2021122284A (es)
TW (2) TWI750122B (es)
WO (1) WO2016201049A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788863T3 (es) 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018234506A2 (en) * 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
EP3622523B1 (en) 2017-10-16 2024-03-06 Illumina, Inc. Semi-supervised learning for training an ensemble of deep convolutional neural networks
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
WO2019204663A1 (en) * 2018-04-19 2019-10-24 Neon Therapeutics, Inc. Peptide formulations and uses thereof
IL321689A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Vaccines against breast cancer
WO2020022898A2 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
WO2020131586A2 (en) * 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
JP7665205B2 (ja) * 2019-03-11 2025-04-21 エヴァクシオン・バイオテック・アクティエセルスカブ ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
CN114845745A (zh) * 2019-10-03 2022-08-02 维特鲁维亚控股有限公司 结缔组织修复方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN113461805B (zh) * 2021-09-02 2021-12-10 广州吉妮欧生物科技有限公司 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
WO1992014486A1 (en) 1991-02-22 1992-09-03 THE UNITED STATES OF AMERICA as represented by THE SECRETARY, THE U.S. DEPARTMENT OF COMMERCE Transmission blocking vaccine against malaria
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
JP3911010B2 (ja) 1994-04-29 2007-05-09 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1999015685A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
CA2374597A1 (en) 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
HU228691B1 (en) 2000-03-14 2013-05-28 Bavarian Nordic As Altered strain of the modified vaccina virus ankara (mva)
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PT1335987E (pt) 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
IL163701A0 (en) 2002-04-19 2005-12-18 Bavarian Nordic As Modified vaccinia virus ankara for the vaccinationof neonates
UA84024C2 (ru) 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
RU2285548C2 (ru) * 2004-10-25 2006-10-20 Георгий Цыренович Дамбаев Способ лечения онкозаболеваний
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
WO2008118691A2 (en) * 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス，インコーポレイテッド 心不全の治療用のｒｎａ干渉
ES2788863T3 (es) * 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
RU2670745C9 (ru) * 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
CA2908434C (en) * 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
JP6740127B2 (ja) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤

Also Published As

Publication number Publication date
JP2018521028A (ja) 2018-08-02
ECSP18001613A (es) 2018-05-31
MX2017015881A (es) 2018-04-18
CN107921107A (zh) 2018-04-17
RU2753246C2 (ru) 2021-08-12
RU2017145963A (ru) 2019-07-16
PE20180601A1 (es) 2018-04-09
TW202241500A (zh) 2022-11-01
PH12017502233A1 (en) 2018-06-25
CO2017012893A2 (es) 2018-05-21
TW201718000A (zh) 2017-06-01
CA2988135A1 (en) 2016-12-15
AU2016276704A1 (en) 2017-12-14
US20190060428A1 (en) 2019-02-28
CL2019003264A1 (es) 2020-02-14
CR20180015A (es) 2018-03-20
HK1253271A1 (zh) 2019-06-14
WO2016201049A3 (en) 2017-02-09
IL256173A (en) 2018-02-28
KR20180016531A (ko) 2018-02-14
EP3307303A2 (en) 2018-04-18
JP2021152053A (ja) 2021-09-30
RU2017145963A3 (es) 2019-07-17
TWI750122B (zh) 2021-12-21
HK1252325A1 (zh) 2019-05-24
RU2021122284A (ru) 2021-10-21
WO2016201049A2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112016012862A2 (pt) formulações para vacinas para neoplasia
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX385845B (es) Usos y composiciones de la flagelina
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
BR112017012804A2 (pt) composições para higiene bucal e métodos de uso.
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MA45381A (fr) Formulation de vaccin contre le vih
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
GB2556002B (en) Methods and compositions for nanoemulsion vaccine formulations
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
EP3270897A4 (en) Immunogenic compositions for use in vaccination against bordetella
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2018007128A (es) Composiciones para barnices dentales y metodos para su elaboracion y uso.
MX2017001649A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX380433B (es) Combinación de trazodona y gabapentina para el tratamiento de dolor.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih
PL406972A1 (pl) Sposób otrzymywania kompozycji zawierającej klotrimazol oraz kompozycja farmaceutyczna uzyskana tym sposobem